Steven Cohen's IKT Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 40,383 shares of Inhibikase Therapeutics, Inc. (IKT) worth $67,843, representing 0.00% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Steven Cohen has initiated a new position in IKT, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Inhibikase Therapeutics (IKT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Inhibikase Therapeutics (IKT) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +40,383 | New Buy | 40,383 | $1.68 |
Steven Cohen's Inhibikase Therapeutics Investment FAQs
Steven Cohen first purchased Inhibikase Therapeutics, Inc. (IKT) in Q1 2026, acquiring 40,383 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Inhibikase Therapeutics, Inc. (IKT) for 1 quarters since Q1 2026.
Steven Cohen's largest addition to Inhibikase Therapeutics, Inc. (IKT) was in Q1 2026, adding 40,383 shares worth $67,843.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 40,383 shares of Inhibikase Therapeutics, Inc. (IKT), valued at approximately $67,843.
As of the Q1 2026 filing, Inhibikase Therapeutics, Inc. (IKT) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Inhibikase Therapeutics, Inc. (IKT) was 40,383 shares, as reported at the end of Q1 2026.